McAllister Mark, Flanagan Talia, Cole Susan, Abend Andreas, Kotzagiorgis Evangelos, Limberg Jobst, Mead Heather, Mangas-Sanjuan Victor, Dickinson Paul A, Moir Andrea, Pepin Xavier, Zhou Diansong, Tistaert Christophe, Dokoumetzidis Aristides, Anand Om, Le Merdy Maxime, Turner David B, Griffin Brendan T, Darwich Adam, Dressman Jennifer, Mackie Claire
Pfizer WWRD, Sandwich, Kent CT13 9NJ, UK.
UCB Pharma SA, 1420 Braine l'Alleud, Belgium.
Pharmaceutics. 2022 May 7;14(5):1010. doi: 10.3390/pharmaceutics14051010.
A webinar series that was organised by the Academy of Pharmaceutical Sciences Biopharmaceutics focus group in 2021 focused on the challenges of developing clinically relevant dissolution specifications (CRDSs) for oral drug products. Industrial scientists, together with regulatory and academic scientists, came together through a series of six webinars, to discuss progress in the field, emerging trends, and areas for continued collaboration and harmonisation. Each webinar also hosted a Q&A session where participants could discuss the shared topic and information. Although it was clear from the presentations and Q&A sessions that we continue to make progress in the field of CRDSs and the utility/success of PBBM, there is also a need to continue the momentum and dialogue between the industry and regulators. Five key areas were identified which require further discussion and harmonisation.
制药科学学院生物药剂学焦点小组于2021年组织的一系列网络研讨会聚焦于口服药品制定临床相关溶出度规范(CRDSs)所面临的挑战。工业界科学家与监管机构及学术界科学家通过一系列六场网络研讨会齐聚一堂,讨论该领域的进展、新趋势以及持续合作与协调的领域。每场网络研讨会还设有问答环节,参与者可以讨论共同的主题和信息。尽管从演讲和问答环节中可以明显看出,我们在CRDSs领域以及生理药代动力学-药效学模型(PBBM)的实用性/成功方面继续取得进展,但行业与监管机构之间仍需要保持这一势头并继续对话。确定了五个关键领域,需要进一步讨论和协调。